The global fibrotic diseases treatment market is experiencing significant growth due to the rising prevalence of chronic fibrotic disorders, including idiopathic pulmonary fibrosis (IPF), liver fibrosis, kidney fibrosis, and cardiac fibrosis. Increased awareness, advancements in antifibrotic therapies, and a growing pipeline of innovative drugs are driving market expansion. Leading pharmaceutical companies such as Boehringer Ingelheim, Roche, and Teva are investing heavily in novel treatment approaches, including combination therapies and biologics. The demand for targeted therapies and immunomodulators is increasing as research uncovers new pathways for fibrosis progression. In addition, government initiatives, orphan drug designations, and rising healthcare expenditure are fueling market growth. However, high treatment costs and limited therapeutic options remain key challenges. With ongoing clinical trials and regulatory approvals, the market is expected to expand further, offering improved patient outcomes and innovative therapeutic solutions.
Global Fibrotic Diseases Treatment Market is valued at 5.79 billion in 2024 and is expected to reach USD 10.35 billion by 2032, with a growing CAGR of 4.71% during the forecast period 2025 to 2032.
To know more, visit https://www.databridgemarketresearch.com/reports/global-fibrotic-diseases-treatment-market
Below are the Top Fibrotic Diseases Treatment Companies with a Significant Market Share:
|
Rank
|
Company
|
Overview
|
Product Portfolio
|
Sales Geographical Coverage
|
Developments
|
|
1.
|
Boehringer Ingelheim International GmbH
|
Boehringer Ingelheim is a leading pharmaceutical company specializing in respiratory diseases, oncology, and fibrotic disorders. The company's OFEV (nintedanib) is a key treatment for idiopathic pulmonary fibrosis (IPF) and other progressive fibrotic interstitial lung diseases. Boehringer Ingelheim continues to invest in research for novel antifibrotic therapies, strengthening its position in the market.
|
|
North America, South America, Middle East and Africa, Asia-Pacific, and Europe
|
In September 2024, Boehringer Ingelheim International GmbH announced that the FIBRONEER-IPF trial met its primary endpoint of FVC improvement at week 52, and it plans to submit a new drug application for nerandomilast for IPF treatment to the FDA and other global authorities. This successful trial and upcoming submission will strengthen Boehringer Ingelheim’s position in the competitive IPF market, potentially expanding its respiratory drug portfolio.
|
|
2.
|
Genentech, Inc. (A subsidiary of F. Hoffmann-La Roche Ltd)
|
Genentech, a biotechnology subsidiary of F. Hoffmann-La Roche Ltd., plays a crucial role in the Global Fibrotic Diseases Treatment Market by focusing on innovative antifibrotic therapies. The company is a key player in the treatment of idiopathic pulmonary fibrosis (IPF) through its flagship drug, Esbriet (pirfenidone), which helps slow disease progression. Genentech is actively engaged in clinical trials and research aimed at developing next-generation targeted and immunomodulatory therapies for various fibrotic conditions, including lung, liver, and kidney fibrosis. With its strong expertise in biologic and small-molecule drug development, the company continues to drive advancements in precision medicine and personalized treatment approaches for fibrotic diseases.
|
|
North America
|
In March 2021, Genentech, a member of the Roche Group announced that the Phase III SKYSCRAPER-02 study, evaluating the investigational anti-TIGIT immunotherapy tiragolumab plus Tecentriq (atezolizumab) and chemotherapy (carboplatin and etoposide) as an initial (first-line) treatment for people with extensive-stage small cell lung cancer (ES-SCLC), did not meet its co-primary endpoint of progression-free survival. This has helped the company to expand globally.
|
|
3.
|
Teva Pharmaceutical Industries Ltd.
|
Teva is a major generic and specialty pharmaceutical company, providing cost-effective alternatives for fibrotic disease treatments. While Teva does not have a proprietary fibrosis drug, the company plays a role in distributing and developing generic versions of antifibrotic medications, enhancing market accessibility.
|
|
North America, Middle East and Africa, Asia-Pacific, and Europe
|
In July 2024, Teva and Sanofi announced an updated timeline for the anti-TL1A program, duvakitug, a monoclonal antibody targeting TL1A for moderate-to-severe IBD. Advancing this program strengthens both companies’ positions in the IBD treatment market, potentially expanding their offerings in immunology.
|
|
4.
|
Sandoz Group AG
|
Sandoz, a subsidiary of Novartis, is a leader in biosimilars and generic medicines, including treatments for chronic respiratory and fibrotic conditions. The company focuses on affordable access to key therapies for fibrosis-related diseases, ensuring a competitive presence in the global market.
|
|
North America, South America, Middle East and Africa, Asia-Pacific, and Europe
|
In November 2022, Sandoz International GmbH, a global leader in generic and biosimilar medicines, today announced an additional investment of EUR 50 million to support increased European manufacturing capacity for finished dosage form (FDF) penicillins, the leading class of antibiotics worldwide. This has helped the company to expand globally.
|
|
5.
|
Accord Healthcare
|
Accord Healthcare specializes in generic and biosimilar medicines, contributing to the affordability of fibrotic disease treatments. The company’s strategic focus includes developing alternatives to branded antifibrotic drugs, helping expand patient access worldwide.
|
Generic pirfenidone
|
North America and Europe
|
In June 2022, Accord Healthcare, Inc., a leading generic pharmaceutical company, has added Pirfenidone to its oral solid products portfolio. The new drug is therapeutically equivalent to Genentech's Esbriet and approved to treat idiopathic pulmonary fibrosis (IPF), a lung disease that involves scarring of the lungs with an unknown cause.1 The new product, offered in 267 mg and 801 mg tablets, is currently available to ship. This has helped the company to expand globally.
|
Conclusion
The global fibrotic diseases treatment market is poised for continued expansion, driven by the increasing prevalence of chronic fibrotic disorders and advancements in antifibrotic therapies. Leading pharmaceutical companies are heavily investing in research and development, focusing on novel drug formulations, combination therapies, and biologics to enhance treatment efficacy. Despite challenges such as high treatment costs and limited therapeutic options, the market is benefiting from government support, orphan drug designations, and rising healthcare investments. The growing emphasis on precision medicine and targeted therapies is expected to further propel market growth. With ongoing clinical trials and regulatory approvals, the market is set to evolve, offering enhanced treatment options and improved patient outcomes in the coming years.
